Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Oncology Reports
|
December 5, 2003
Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma
Alessandro Morabito, Massimo Fanelli, Guido Carillio, et al.
Critical Reviews in Oncology/Hematology
|
December 13, 2005
Is tailored therapy feasible in oncology?
Giampietro Gasparini, Raffaele Longo, Francesco Torino, et al.
Journal of Gastrointestinal Cancer
|
January 29, 2013
Atypical multiple ileum metastases of renal cell carcinoma
Raffaele Longo, Domenico Gattuso, Roberto Luchetti, et al.
Recenti Progressi in Medicina
|
December 20, 2002
[Innovative treatment in oncology]
Barbara Capaccetti, Paola Bonginelli, Roberta Sarmiento, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2011
Primary nongestational choriocarcinoma of the uterine cervix
Raffaele Longo, Francesco Battaglia, Domenico Gattuso, et al.
Clinical Breast Cancer
|
March 15, 2003
Prognostic and predictive indicators in operable breast cancer
Alessandro Morabito, Elena Magnani, Massimo Gion, et al.
Expert Opinion on Investigational Drugs
|
July 2, 2003
Thalidomide: a new anticancer drug?
Massimo Fanelli, Roberta Sarmiento, Domenico Gattuso, et al.
The Oncologist
|
October 27, 2005
Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer
Giampietro Gasparini, Domenico Gattuso, Alessandro Morabito, et al.
International Journal of Gastrointestinal Cancer
|
February 10, 2007
Multiorganic dissemination of a colorectal signet ring cell carcinoma with fulminant clinical course
Raffaele Longo, Alessandro Morabito, Guido Carillio, et al.
Breast Cancer Research and Treatment
|
March 4, 2003
The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study
Alessandro Morabito, Gianfranco Filippelli, Sergio Palmeri, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Oncology Reports
|
December 5, 2003
Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma
Alessandro Morabito, Massimo Fanelli, Guido Carillio, et al.
Critical Reviews in Oncology/Hematology
|
December 13, 2005
Is tailored therapy feasible in oncology?
Giampietro Gasparini, Raffaele Longo, Francesco Torino, et al.
Journal of Gastrointestinal Cancer
|
January 29, 2013
Atypical multiple ileum metastases of renal cell carcinoma
Raffaele Longo, Domenico Gattuso, Roberto Luchetti, et al.
Recenti Progressi in Medicina
|
December 20, 2002
[Innovative treatment in oncology]
Barbara Capaccetti, Paola Bonginelli, Roberta Sarmiento, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2011
Primary nongestational choriocarcinoma of the uterine cervix
Raffaele Longo, Francesco Battaglia, Domenico Gattuso, et al.
Clinical Breast Cancer
|
March 15, 2003
Prognostic and predictive indicators in operable breast cancer
Alessandro Morabito, Elena Magnani, Massimo Gion, et al.
Expert Opinion on Investigational Drugs
|
July 2, 2003
Thalidomide: a new anticancer drug?
Massimo Fanelli, Roberta Sarmiento, Domenico Gattuso, et al.
The Oncologist
|
October 27, 2005
Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer
Giampietro Gasparini, Domenico Gattuso, Alessandro Morabito, et al.
International Journal of Gastrointestinal Cancer
|
February 10, 2007
Multiorganic dissemination of a colorectal signet ring cell carcinoma with fulminant clinical course
Raffaele Longo, Alessandro Morabito, Guido Carillio, et al.
Breast Cancer Research and Treatment
|
March 4, 2003
The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study
Alessandro Morabito, Gianfranco Filippelli, Sergio Palmeri, et al.
Page
of 2